Status and phase
Conditions
Treatments
About
The aim of this study is to evaluate the effectiveness and safety of a combined Traumeel® / Zeel® injection against placebo (saline) in patients with moderate-to-severe pain associated with osteoarthritis of the knee.
Full description
The primary objective is to demonstrate the superiority of Traumeel® and Zeel® co-administered intra-articular (IA) injections vs placebo IA injections on the change in knee pain in patients with moderate to severe knee pain associated with osteoarthritis.
The secondary objectives are to evaluate reduction of pain and stiffness and change in physical function.
Safety is evaluated by the incidence of treatment emergent adverse events during the treatment period and follow up period for all randomized patients.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria (Screening Visit 1):
Osteoarthritis (OA) of the knee by American College of Rheumatology criteria
Men or women between 45-80 years of age.
Have documented diagnosis of primary OA of the target knee based on clinical and radiographic criteria (Kellgren-Lawrence Numerical Grading System of Grade 2-3) in the tibial-femoral compartment of the target knee confirmed by standard post-anterior weightbearing X-ray of the knee in full extension taken </= 6 months prior to Visit 1.
Currently taking an Nonsteroidal anti-inflammatory drug (NSAID), or acetaminophen on a regular basis (4-7 days/ week) over last 2 weeks prior to Visit 1 and has experienced amelioration of pain on these medications.
Must have a 50-foot walk test pain score of less than 40 mm on a 100 mm VAS in the target knee at screening
Pain in the non-target (contralateral) knee must not be greater than 30 mm on a 100 mm VAS on 50-foot walk test, and the target knee must be more symptomatic.
Willingness to stop all OA treatments.
Fully informed of the risks of entering the study and willing to provide written consent to enter the study.
Able to understand and be willing to comply with all study requirements, particularly the weekly injection regimen for administration of study drug.
Primary complaint is pain immediately following an unassisted 50-foot walk. They must show:
Exclusion Criteria:
Known hypersensitivity or allergy to any of the components of Traumeel or Zeel
Known hypersensitivity or allergy to acetaminophen.
Has body mass index (BMI) >38 kg/m2.
Avoidance of, or aversion to, nonprescription medications.
Clinical symptoms of meniscal instability or significant valgus/ varus that requires corrective osteotomy
Any major injury or surgery to the target knee in the prior 12 months.
One or a combination of the following co-morbidities:
Participated in any experimental drug or device study within the prior one (1) month and/or IA injections six (6) months.
Referred pain from other joints
Significantly debilitating concurrent infection(s)
Significant ligamentous instability
Any prior viscosupplementation therapy (in target knee) within 6 months prior to Screening
Systemic or IA injection of corticosteroids in any joint within 3 months of enrollment
Therapy with oral hyaluronic acid products, and/or oral pharmaceutical products containing glucosamine and/or chondroitin sulphate and/or diacerein
Therapy with opioids within the last 90 days including intra-dermal delivery systems (patches)
Therapy with autologous stem cells
Therapy with coumarins such as warfarin, Coumadin; heparin and derivative substances including low molecular weight heparin, synthetic pentasaccharide inhibitors of factor Xa such as fondaparinux and idraparinux; direct factor Xa inhibitors such as rivaroxaban and apixaban; direct thrombin inhibitors such as hirudin, lepirudin, bivalirudin, argatroban and dabigatran.
Concomitant inflammatory or other rheumatologic, neurological or cardiovascular diseases which could affect the evaluation of knee pain
Ongoing litigation for workers compensation for musculoskeletal injuries or disorders
Use of alcohol of more than 4 drinks per day
Clinically important axial deviation (varus, valgus) greater than 15 degrees
Concomitant severe OA of the hip or other joints, which might interfere with the assessments required by the study
Painful knee conditions other than OA (e.g., Paget's disease)
Hemiparesis of lower limbs
Significant planned surgery to lower limbs, which might interfere with the patient's ability to comply with study requirements
Presence of serious gastrointestinal, renal, hepatic, pulmonary, cardiovascular, neurological disease that might interfere with the outcome of the study or the patient's ability to comply with study requirements
Presence of infections and/or skin diseases in the area of the injection site such as psoriasis
Females who are pregnant or breast-feeding or not using recognized effective contraceptive measures. Females of childbearing potential (including those less than one year post-menopausal) must agree to maintain reliable birth control throughout the study.
Clinically significant abnormal laboratory values.
Patients who are likely to be non-compliant or uncooperative during the study.
Primary purpose
Allocation
Interventional model
Masking
287 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal